Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Cagrilintide: The Next Gen Peptide for Weight Loss and Satiety Hubmed Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48 week phase 2, multicentre, double blind, randomised, placebo controlled trial The Lancet When should I consider adding cagrilintide? Cagrilintide is the newest of the weight loss peptides. It works on amylin, which is found in the pancreas. Now, this can be a stand alone product but the Cagrilintide: What It Is and How It's Being Studied for Weight Loss Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants Gabe 2024 Diabetes, Obesity and Metabolism Wiley Online Library